CAS 1035094-10-0 Iloprost-[d4] (Major)

General Information
Catalog: BLP-005867
CAS: 1035094-10-0
Molecular Formula: C22H28D4O4
Molecular Weight: 364.51

General Information

Catalog: BLP-005867

CAS: 1035094-10-0

Molecular Formula: C22H28D4O4

Molecular Weight: 364.51

Chemical Structure

Description	Iloprost-[d4] is a labelled analogue of Iloprost. A labelled synthetic analogue of Prostacyclin (PGI2) used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and ischemia. It acts through elevation of cAMP by binding to the prostacyclin receptor (IP receptor). Iloprost inhibits the ADP, thrombin. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time.
Synonyms	(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic Acid-d4; (1S,2R,3R,5S)-7-[(E)-4-Carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane-d4; Ciloprost-d4; Endoprost-d4
IUPAC Name	(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]-2,2,3,3-tetradeuteriopentanoic acid
Related CAS	78919-13-8 (unlabelled)
Canonical SMILES	CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O
InChI	InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1/i6D2,9D2
InChI Key	HIFJCPQKFCZDDL-KFJXZQTLSA-N
Purity	98% by CP; 98% atom D
Appearance	Colorless to Pale Yellow Oil to Low-Melting Solid
Storage	Store at -20°C

Iloprost-[d4] (Major) is a deuterated derivative of Iloprost, a potent prostacyclin analog known for its robust vasodilatory effects. Below are the key applications of Iloprost-[d4] (Major) explored with a high degree of perplexity and burstiness:

Pharmacokinetic Studies: Utilizing Iloprost-[d4] in pharmacokinetic investigations grants researchers a deep understanding of how Iloprost is absorbed, distributed, metabolized, and excreted within the body. The deuterium-labeling enhances precision in tracking and quantifying the drug's behavior, employing cutting-edge mass spectrometry techniques. This meticulous approach aids in optimizing dosing regimens and ensuring the maximum therapeutic efficacy of the drug.

Pulmonary Arterial Hypertension Research: Positioned as a cornerstone in the realm of pulmonary arterial hypertension (PAH) research, Iloprost-[d4] becomes a vital instrument for delving further into this complex condition. Through the utilization of the deuterated form, researchers gain the ability to discern between endogenous and exogenous levels of the compound, thereby enabling a more thorough investigation into its therapeutic mechanisms. This comprehensive understanding supports the refinement of treatment strategies for PAH, pushing the boundaries of medical innovation.

Drug Interaction Studies: In the domain of drug interaction studies, Iloprost-[d4] plays a crucial role in assessing the interactions between Iloprost and other medications. By leveraging the deuterated version, scientists can trace specific metabolic pathways and pinpoint potential interactions with other drugs that undergo similar metabolic processes.